Cargando…

Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies

This review reflects the presentations and discussion at the 14th post-American Society of Hematology (ASH) International Workshop on Chronic Myeloproliferative Malignancies, which took place on the December 10 and 11, 2019, immediately after the 61st ASH Annual Meeting in Orlando, Florida. Rather t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mughal, Tariq I., Pemmaraju, Naveen, Psaila, Bethan, Radich, Jerald, Bose, Prithviraj, Lion, Thomas, Kiladjian, Jean-Jacques, Rampal, Raajit, Jain, Tania, Verstovsek, Srdnan, Yacoub, Abdulraheem, Cortes, Jorge E., Mesa, Ruben, Saglio, Giuseppe, van Etten, Richard A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895354/ https://www.ncbi.nlm.nih.gov/pubmed/32592408 http://dx.doi.org/10.1002/hon.2771

Ejemplares similares

Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021
por: Mughal, Tariq I., et al.
Publicado: (2021)

Chronic Myeloproliferative Neoplasms: Some Remaining Challenges
por: Mughal, Tariq I., et al.
Publicado: (2018)

Children and Adolescents with Chronic Myeloproliferative Neoplasms: Still an Unmet Biological and Clinical Need?
por: Mughal, Tariq I., et al.
Publicado: (2019)

Targeted therapies for myeloproliferative neoplasms
por: Li, Bing, et al.
Publicado: (2019)

Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure
por: Alhuraiji, Ahmad, et al.
Publicado: (2017)

P1018: UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SAFETY OF PELABRESIB (CPI-0610) AS ADD-ON TO RUXOLITINIB IN MYELOFIBROSIS
por: Kremyanskaya, Marina, et al.
Publicado: (2023)

Message in a platelet: decoding platelet transcriptomes in myeloproliferative neoplasms
por: Shapiro, Susan, et al.
Publicado: (2021)

Application of Single-Cell Approaches to Study Myeloproliferative Neoplasm Biology
por: Royston, Daniel, et al.
Publicado: (2021)

The immune landscape in BCR‐ABL negative myeloproliferative neoplasms: inflammation, infections and opportunities for immunotherapy
por: Strickland, Marie, et al.
Publicado: (2021)

Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges
por: Ajufo, Helen O., et al.
Publicado: (2023)

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
por: Mascarenhas, J, et al.
Publicado: (2012)

Ruxolitinib: Long-Term Management of Patients with Myelofibrosis and Future Directions in the Treatment of Myeloproliferative Neoplasms
por: Yacoub, A., et al.
Publicado: (2014)

Myeloproliferative neoplasms
por: Kiladjian, Jean-Jacques
Publicado: (2018)

P1016: RUSFERTIDE (PTG-300) IMPROVES POLYCYTHEMIA VERA (PV) RELATED SYMPTOMS IN PV PATIENTS
por: Kuykendall, Andrew, et al.
Publicado: (2023)

Ruxolitinib for essential thrombocythemia?
por: Bose, Prithviraj, et al.
Publicado: (2017)

Updates in the management of polycythemia vera and essential thrombocythemia
por: Bose, Prithviraj, et al.
Publicado: (2019)

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives
por: Bose, Prithviraj, et al.
Publicado: (2020)

MF management
por: Bose, Prithviraj, et al.
Publicado: (2019)

Atypical Presentation of Erythroid/Megakaryocytic Leukemic Transformation of a Myeloproliferative Neoplasm Associated with Mutation and Loss of TP53
por: Chernak, Brian J., et al.
Publicado: (2020)

Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis
por: Gupta, Vikas, et al.
Publicado: (2023)

Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
por: Verstovsek, Srdan, et al.
Publicado: (2021)

Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms
por: Bose, Prithviraj, et al.
Publicado: (2020)

Momelotinib: an emerging treatment for myelofibrosis patients with anemia
por: Chifotides, Helen T., et al.
Publicado: (2022)

Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments
por: Chifotides, Helen T., et al.
Publicado: (2023)

Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells
por: Fiskus, Warren, et al.
Publicado: (2022)

Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis
por: Pemmaraju, Naveen, et al.
Publicado: (2022)

P1066: OUTCOMES OF COVID-19 IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS - AN OBSERVATIONAL COHORT STUDY FROM A LARGE ACADEMIC CANCER CENTER IN THE UNITED STATES
por: Venugopal, S., et al.
Publicado: (2022)

Myelodysplastic/Myeloproliferative Neoplasms, Unclassifiable (MDS/MPN, U): Natural history and clinical outcome by treatment strategy
por: DiNardo, CD, et al.
Publicado: (2014)

P1027: UPDATED DURABILITY OF RESPONSE AND SAFETY IN MANIFEST ARM 3: PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB FOR JAK INHIBITOR TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS
por: Harrison, Claire, et al.
Publicado: (2023)

BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells
por: Saenz, Dyana T., et al.
Publicado: (2016)

Solving the Mystery of Myelodysplasia
por: Radich, Jerald
Publicado: (2008)

Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
por: Talpaz, Moshe, et al.
Publicado: (2020)

Biological drivers of clinical phenotype in myelofibrosis
por: Mascarenhas, John, et al.
Publicado: (2022)

Abdominal venous thrombosis presenting in myeloproliferative neoplasm with JAK2 V617F mutation: a case report
por: Pemmaraju, Naveen, et al.
Publicado: (2012)

Characterization of disease-propagating stem cells responsible for myeloproliferative neoplasm–blast phase
por: Wang, Xiaoli, et al.
Publicado: (2022)

Long-Term Hematologic Improvement in a Patient With Cytopenic Myelofibrosis Treated With Pacritinib
por: Yacoub, Abdulraheem, et al.
Publicado: (2023)

Another Philadelphia story*
por: Radich, Jerald P.
Publicado: (2022)

P986: COMBINATION JAK1/2 AND CDK8/19 INHIBITION DEMONSTRATES ENHANCED EFFICACY IN MYELOPROLIFERATIVE NEOPLASMS
por: Zaroogian, Zachary, et al.
Publicado: (2023)

A tale of two alleles: TP53 and transformation in MPNs
por: Brierley, Charlotte, et al.
Publicado: (2022)

Serum antibody response in patients with philadelphia-chromosome positive or negative myeloproliferative neoplasms following vaccination with SARS-CoV-2 spike protein messenger RNA (mRNA) vaccines
por: Kozak, Kathryn E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u09e2qnbs7efspdteljhis06f9